1. Mark Foster
Replace this photo with your own by going to Insert  Photo  Picture from File.

2. Number of patients treated by year

3. Recorded yearly usage

4. Year
% Increase Usage
2011/12
13%
2012/13
11%
2013/14
15%
2014/15
16%

5. Average yearly usage

6. Number of patients treated by region

7. Yearly Usage by Region

8. Average patient usage by region

9. Number of patients treated by Speciality

10. Yearly Usage by Speciality

11. Average patient usage by speciality

12. Average patient usage - Haematology
Condition
Grams 14/15
ITP Acute
222,526
ITP Persistent
54,140

13. Average patient usage - Immunology
Condition
Grams 14/15
PID
1,102,219
Secondary
225,344
Specific
46,058

14. Average patient usage by - Neurology
Condition
Grams 14/15
CIDP
859,480
MMN
411,494 MG
173,893 GB
142,285 IM
97,308

15. Average patient usage by indication & regime

16. Year
2011/12
2012/13
2013/14
20141/15
Grey Usage
263,445
301,859
315,143
354,744

17. Grey Requests 1028 1404 1424 1331 Outcomes n/a 433 326 307 Percentage
Year
2011/12
2012/13
2013/14
20141/15
Grey Requests
1028
1404
1424
1331
Outcomes
n/a
433
326
307
Percentage
31%
23%

18. Yearly usage by product type

19. Yearly intravenous product usage

20. Yearly subcutaneous product usage

21. CIDP Analysis – Patients treated & Recorded Usage

22. CIDP Analysis – Average Usage

23. ITP Acute Dosing
G per KG
Percentage 1g
30% 2g
55%
>2g
15%

24. Diagnosis Criteria Met
Percentage
Yes
96 % No
0.3%
N/A
3.7%

25. Conclusions Database capturing higher percentage of national usage
Usage increasing overall
Database can help to identify cost saving opportunities
Updated guidelines required as part of national strategy
Database now able to accommodate studies into immunoglobulin usage
Investigate average use increases

26. In need of IT Services? info@mdsas.com
THANK YOU
In need of IT Services?

27. 2
Condition analysis

28. Afternoon session Version 5 run through
Version 5 – First look & have your say
Dashboards Update